Patents by Inventor Bailin Hu

Bailin Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused ring compounds as hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
    Patent number: 9802949
    Abstract: Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X?, Y, Y?, A, A?, Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: October 31, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Jiancun Zhang, Hongming Xie, Qingyun Ren, Shifeng Li, Changping Fu, Bailin Hu, Xiwei Wu, Changhua Tang
  • Bridged ring compounds as Hepatitis C virus inhibitors, pharmaceutical compositions and uses thereof
    Patent number: 9738629
    Abstract: Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus C(HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.
    Type: Grant
    Filed: January 22, 2015
    Date of Patent: August 22, 2017
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Hongming Xie, Jiancun Zhang, Bailin Hu, Qinghong Fang, Qingyun Ren
  • BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20170044140
    Abstract: Provided herein is a bridged bring compound of formula (I) or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating treat hepatitis C virus (HCV) infection or hepatitis C disease. Furthermore provided herein are pharmaceutical compositions containing the compounds and the method of using the compounds or pharmaceutical compositions thereof in the treatment of HCV infection or hepatitis C.
    Type: Application
    Filed: January 22, 2015
    Publication date: February 16, 2017
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Hongming XIE, Jiancun ZHANG, Bailin HU, Qinghong FANG, Qingyun REN
  • Spiro ring compound as hepatitis C virus (HCV) inhibitor and uses thereof
    Patent number: 9416139
    Abstract: A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.
    Type: Grant
    Filed: November 28, 2013
    Date of Patent: August 16, 2016
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiancun Zhang, Yingjun Zhang, Hongming Xie, Qingyun Ren, Bailin Hu, Changping Fu, Xiwei Wu, Shifeng Li, Chenglin Wang, Zhikeng Zhang
  • FUSED RING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
    Publication number: 20150307509
    Abstract: Provided are fused tricyclic compounds effective to inhibit the function of the NS5A protein of formula (I), wherein X, X?, Y, Y?, A, A?, Q1, Q2, R1-R4, X4, R5a, f and W are defined as in the description. Also provided herein are pharmaceutical compositions thereof, and uses in the manufacture of a medicament for treating HCV infection or a HCV disorder thereof.
    Type: Application
    Filed: November 28, 2013
    Publication date: October 29, 2015
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Jiancun ZHANG, Hongming XIE, Qingyun REN, Shifeng LI, Changping FU, Bailin HU, Xiwei WU, Changhua TANG
  • SPIRO RING COMPOUND AS HEPATITIS C VIRUS (HCV) INHIBITOR AND USES THEREOF
    Publication number: 20150299215
    Abstract: A compound of formula (I) or a stereoisomer, a geometric isomer. a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.
    Type: Application
    Filed: November 28, 2013
    Publication date: October 22, 2015
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Jiancun Zhang, Yingjun Zhang, Hongming Xie, Qingyun Ren, Bailin Hu, Changping Fu, Xiwei Wu, Shifeng Li, Chenglin Wang, Zhikeng Zhang
  • SPIRO RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS
    Publication number: 20150232509
    Abstract: A compound of formula (I) or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof is provided, which can be used for treating HCV infection or a HCV disorder. Also a pharmaceutical composition comprising the compound and the use of the compound and the pharmaceutical composition thereof are provided, which can also be used for treating HCV infection or a HCV disorder.
    Type: Application
    Filed: September 29, 2013
    Publication date: August 20, 2015
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Jiancun Zhang, Hongming Xie, Qingyun Ren, Xiwei Wu, Huichao Luo, Changping Fu, Bailin Hu, Shifeng Li, Changhua Tang, Yong Lei, Quanxing Yu, Qinghong Fang, Chenglin Wang